WIN Symposium

Memo

After this activity, participants should be able to:1. Recognize established and emerging biomarkers with diagnostic, prognostic, or predictive value in contemporary cancer management2. Learn best practices in using biomarker-based algorithms for cancer treatment selection, optimization, and monitoring3. Understand design specifics and clinical implications of research studies and clinical trials assessing new biomarkers for immunotherapy and targeted therapy4. Realize how principles of precision oncology can be applied to radiation therapy5. Appreciate issues of access, diversity and equity in precision oncology practice and clinical trials Date and Time: Friday March 01, 2024 at 08:30 to Saturday March 02, 2024 at 16:00 Venue details: Rosewood Abu Dhabi, Al Maryah Island, Abu Dhabi, United Arab Emirates Prices:Academic/ Non-profit (Early Bird): AED 1100.00,Industry: AED 1280.00,Students/ Residents: AED 368.00 Speakers: Prof. James Allison, PhD, Nobel Laureate 2018, Department of Immunology Vice President of Immunobiology Executive Director, Immunotherapy Platform Director, James P. Allison Institute Olga Keith Wiess Distinguished University Chair of Cancer Research MD Anderson Cancer Center (TX, USA), Prof. Wafik El-Deiry, MD PhD FACP Chair, WIN Consortium American Cancer Society Research Professor Director, Legorreta Cancer Center Associate Dean, Oncologic Sciences, Warren Alpert Medical School Brown University (RI, USA), Prof. Faisal Khan, PhD D(ABHI) CEO, Co-Founder and Director OncoHelix (Canada) in collaboraion with coLAB, Burjeel Holdings (UAE) Professor, Cumming School of Medicine Director, Hematology Translational Lab University of Calgary (Canada) , Dr. Vladimir Lazar, MD PhD Chief Scientific and Operating Officer WIN Consortium (France), Prof. Humaid Al-Shamsi, MD FACP FRCP(Lon) FRCP(Ca) Director of Oncology Services, Burjeel Holdings Professor, Gulf Medical University President, Emirates Oncology Society (UAE), Prof. Razelle Kurzrock, MD Chief Medical Officer / Equal Opportunities and Diversity Officer, WIN Consortium Professor of Medicine, Associate Director, Clinical Research Chair of Precision Oncology, MCW Cancer Center and Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine Founding Director, Michels Rare Cancers Research Laboratories Froedtert and Medical College of Wisconsin (WI, USA)